Answers are grounded in this paper and cite their sources.
// Weiping Wang 1, * , Qingyu Meng 1, * , Xiaorong Hou 1 , Xin Lian 1 , Junfang Yan 1 , Shuai Sun 1 , Zhikai Liu 1 , Zheng Miao 1 , Dunhuang Wang 1 , Xiaoliang Liu 1 , Ke Hu 1 and Fuquan Zhang 1 1 Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China * These authors contributed equally to this work Correspondence to: Ke Hu, email: huk@pumch.cn Fuquan Zhang, email: zhangfuquan3@126.com Keywords: cervical cancer; image-guided radiation therapy; intensity-modulated radiation therapy; dose-escalated brachytherapy; FIGO stage IIB Received: July 14, 2017 Accepted: October 27, 2017 Published: November 15, 2017 ABSTRACT Considering internal organ motion and tumor regression, it is controversial to use intensity-modulated radiation therapy (IMRT) in definitive radiotherapy for cervical cancer. In this study, we evaluated the efficacy and toxicity of IMRT combined with dose-escalated intracavitary brachytherapy (ICBT) for cervical cancer. In total, 373 consecutive FIGO-stage-IIB cervical cancer patients treated with IMRT combined with ICBT and concurrent chemotherapy were included in this study. A dose of 50.4 Gy in 28 fractions was delivered to the pelvis for IMRT. Weekly cone-beam computed tomography or daily megavoltage computed tomography was used for image guiding. For ICBT, 30–36 Gy in five to seven fractions were prescribed to point A. All patients received concurrent chemotherapy. The median follow-up duration was 32.5 months (range, 3.1–119.8 months). The three-year overall survival, disease-free survival and local control rates were 87.5%, 82.2% and 92.5%, respectively. Sixty patients (16.1%) experienced treatment failure, including 23 patients (6.2%) with pelvic relapse. The incidences of ≥grade 3 chronic gastrointestinal and genitourinary toxicity were 2.7% and 2.4%, respectively. These findings indicate that image-guided IMRT combined with dose-escalated ICBT results in good survival with acceptable toxicity in stage IIB cervical cancer patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: